A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Status:
Not yet recruiting
Trial end date:
2027-05-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate if milvexian is atleast as effective as apixaban for
reducing the risk of the composite stroke and non- central nervous system (CNS) systemic
embolism.